Study of Oxaliplatin and Taxotere in Prostate Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The primary objective for this study is to evaluate PSA response rates (response will be
defined as a > 50% reduction in PSA levels) in men who have failed primary chemotherapy. The
secondary objectives are to compare progression free survival, disease free survival, overall
survival, and toxicity (tolerance/safety).